Medical Device News Magazine

WellAir: New FDA-cleared Indoor Cleaning Device 99.9% Effective Indoor Pathogens Including COVID

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

WellAir, the leading health technology company that provides indoor air disinfection solutions, is charting a new path forward for healthy indoor environments at a time when air quality has never been a bigger priority.

Backed by more than a decade of research and innovation, WellAir recently launched the Defend NV 400, an FDA-cleared Class II medical device that is 99.9% effective at inactivating airborne pathogens such as SARS-CoV-2 proxy virus (MS2 Bacteriophage) and MRSA, bacteria, and fungi, and also purifies the air of particulate matter, volatile organic compounds, gases, and odors.

“COVID-19 has focused more attention on indoor air quality and has elevated the importance of safer indoor environments by reducing the risk of exposure to airborne pathogens. This is exactly what the new Defend NV 400 is designed to do,” said WellAir President and CEO Todd M. Pope. “This portable device expands our product portfolio, delivering powerful air cleaning in multiple device sizes. This product launch continues to demonstrate our passion for improving the quality of the air and surfaces each of us interacts with daily.”

The Defend NV 400 features WellAir’s unique, patented NanoStrike™ technology – a transformational method of air disinfection developed by a team of scientists and engineers, which bursts airborne pathogen cells, rapidly inactivating them to help ensure they are no longer a threat of infection. Unlike other technologies, NanoStrike’s effectiveness lies in its ability to inactivate nanosized pathogens on contact. The Defend NV 400’s four-stage pathogen inactivation and filtration process also utilizes medical-grade filters from Camfil® in order to capture bacterial debris, fine and large particles, VOCs, gases, odors, and impurities.

The Defend NV 400 is ideally suited for healthcare settings but is effective in a wide array of indoor environments, such as schools and offices.

As WellAir continues to innovate solutions to one of the world’s most pressing public health challenges – improving the air we breathe – it is supported by aMedical Advisory Board, a diverse group of leading public health, environmental and medical experts. The board works collaboratively to study and advise upon the advancement of indoor air and surface quality with an emphasis on improving respiratory, immunological, oncological, and general public health outcomes.

“Improving indoor air quality is essential to the health and well-being of individuals as well as our communities,” said Dr. Regina Benjamin, Chair of the WellAir Medical Advisory Board. “Indoor spaces are typically two to five times more polluted than outdoor spaces, which is especially concerning since we spend much of our time indoors. The Medical Advisory Board and I look forward to collaborating with WellAir to bring awareness and help find solutions to this public health challenge.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”